濕性老年性黃斑部病變:KOL的洞察

本報告深入探討了濕性老年黃斑部病變 (wAMD) 治療的持續發展，並根據美國和歐洲的關鍵意見領袖 (KOL) 的見解提供了全面的分析。本報告對現有療法和正在研發的療法進行了深入回顧，重點介紹了 Eylea HD、Vabysmo 和 Avastin 等現有療法以及 Axpaxli 和 OPT-302 等新興療法的優點和局限性。我們也探討了家用光學相干斷層掃描 (OCT) 和基因治療等新發展對治療模式的潛在影響。它還解決了管理 wAMD 方面的課題和未滿足的需求，並對未來三到五年治療前景的發展進行了展望。

主要問題

• 目前治療濕性老年黃斑部病變 (wAMD) 的主要方法有哪些？
• 目前 wAMD 治療方法的優點和缺點是什麼？
• 目前 wAMD 治療中尚未滿足的需求和課題是什麼？
• WAMD 目前正在開發哪些產品？
• 預計研發中的藥物將如何影響 wAMD 的治療途徑？
• 未來 3 至 5 年內，wAMD 的治療前景預計會發生怎樣的變化？

領導品牌

調查手法

《治療趨勢》報告是透過對全球領先的關鍵意見領袖 (KOL) 進行深入訪談，了解主要疾病領域的當前和未來治療前景而編寫的。 KOL 是根據嚴格的篩選標準精心挑選出來的，包括全球聲譽、臨床專業知識和其在治療領域的影響力。每次訪談都遵循精心設計的討論指南。這些指南是與 KOL 合作開發的，並經過行業專家的同行評審，以確保問題全面且與當前市場動態相關。透過在每份報告發布後12個月的持續市場監測，我們及時提供來自 KOL 的重大新聞事件、市場變化和市場發展的更新。

我們的報告的特點

FirstWord Reports 是值得信賴的行業領導者，專注於製藥領域，為生物製藥專業人士和決策者提供深入、可行的見解。我們深厚的行業知識使我們能夠提供相關且有價值的見解，幫助我們的客戶了解新興趨勢並有效地解決複雜的課題。我們的報告以廣泛的研究以及來自領先專家和關鍵意見領袖的獨立、公正的見解為後盾，為您提供所需的準確性和可信度。獨家採訪和數據以及持續的市場監控使我們能夠全面了解市場動態。我們的報告涵蓋 40 多個動態疾病領域、包括 KOL 洞察和定量醫生調查在內的醫生情報，以及行業專家對醫療事務、數位健康、銷售和營銷、市場准入和其他領域問題的看法，使您能夠做出更明智的、數據驅動的決策，以在快速變化的行業中保持競爭力。

This report delves into the evolving landscape of wet age-related macular degeneration (wAMD) treatment, offering a comprehensive analysis based on insights from key opinion leaders (KOLs) across the USA and Europe. It provides an in-depth examination of both current and pipeline therapies, highlighting the advantages and limitations of existing treatments such as Eylea HD, Vabysmo, and Avastin, as well as emerging therapies like Axpaxli and OPT-302. The report explores the potential impact of new developments, including at-home optical coherence tomography (OCT) and gene therapies, on treatment paradigms. It also addresses the challenges and unmet needs in wAMD management, offering a forward-looking perspective on how the treatment landscape is expected to evolve over the next 3-5 years.

Key Questions Answered:

• 1. What treatments currently form the backbone of wet age-related macular degeneration (wAMD) therapy?
• 2. What are the advantages and disadvantages of current wAMD treatments?
• 3. What are the current unmet needs and challenges in treating wAMD?
• 4. Which products are currently in the development pipeline for wAMD?
• 5. How are pipeline therapies expected to impact treatment pathways for wAMD?
• 6. How is the treatment landscape for wAMD expected to evolve over the next 3-5 years?

Key Brands:

Partial List of Participating Experts:

• Consultant ophthalmic and retinal surgeon at the London Clinic and the Guthrie Clinic at Kings College Hospital, and Professor of retinal research at Kings College London, London, UK
• Professor of Ophthalmology, University Hospital of Bordeaux, Bordeaux, France
• Head of the Medical retina and imaging unit, Associate Professor of Ophthalmology at Universita Vita-Salute San Raffaele, Milan, Italy
• Director of artificial intelligence and imaging research, Doheny Eye Institute and Professor of Ophthalmology at the University of California- Los Angeles, USA
• Professor of Ophthalmology and Neuroscience at John Hopkins Wilmer eye institute
• Professor and Interim medical professor of the Hietzing clinic, Vienna, Austria

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.